Business Context and Reporting Period
This Form 8-K, dated December 13, 2023, reports the consummation of a business combination between Neoleukin Therapeutics, Inc. (formerly "Neoleukin") and Neurogene Inc. (formerly a Nevada corporation). On December 18, 2023, Neoleukin changed its name to "Neurogene Inc." and the combined entity began trading on The Nasdaq Global Market under the symbol "NGNE." The transaction involved a merger where Neurogene became a wholly-owned subsidiary of the Company. The filing also details a 1-for-4 reverse stock split of Neoleukin common stock effective December 18, 2023.
Key Financial Metrics and Capital Structure
Financing and Liquidity: In connection with the merger, the Company completed a Pre-Closing Financing raising approximately $95 million in gross proceeds. This involved the issuance of 36,934,089 shares of Neurogene Common Stock and 23,964,846 Neurogene Pre-Funded Warrants to financing investors.
Capitalization Post-Closing: As of the Closing Date (December 18, 2023), the Company had 12,823,696 shares of Company Common Stock outstanding. Additionally, there were 4,063,364 Company Pre-Funded Warrants outstanding, each exercisable for one share at $0.000001 per share. Assuming full exercise of these warrants, the total share count would be 16,887,060.
Financial Statements: The filing incorporates by reference unaudited financial statements for Neurogene for the nine months ended September 30, 2023, and audited statements for the years ended December 31, 2022 and 2021. Specific revenue, profit, or cash flow figures for the combined entity are not provided in the text of this 8-K but are referenced in attached exhibits (Exhibits 99.3, 99.4, and 99.5).
Material Changes and Corporate Actions
- Merger Completion: All outstanding Neurogene capital stock (Class A, Class B, Series A-1, A-2, and B Preferred Stock) converted into Company Common Stock at an exchange ratio of 0.0756 shares of Company Common Stock for each share of Neurogene stock.
- Reverse Stock Split: Neoleukin effected a 1-for-4 reverse stock split immediately prior to the merger effective time.
- Authorized Shares: The number of authorized shares of Company Common Stock was increased from 20,000,000 to 500,000,000.
- Executive Departures: Donna M. Cochener (Interim CEO and General Counsel) and Sean Smith (Interim CFO) of Neoleukin were terminated without cause in connection with the change in control. They received separation packages including 125% of annual base salary and target bonus, 15 months of health insurance, and accelerated vesting of equity awards.
- New Leadership: Rachel McMinn was appointed CEO and Chair of the Board. Christine Mikail was appointed President and CFO.
Contingent Value Rights (CVRs)
Holders of Neoleukin Common Stock and pre-funded warrants prior to the merger received one CVR for each share held. These rights entitle holders to potential future payments derived from:
- Net proceeds from the disposition of Neoleukin's pre-merger legacy assets.
- Net savings realized by June 30, 2029, from the reduction of legacy lease obligations.
- Net proceeds from an anticipated Washington State sales tax refund received by June 30, 2029.
- 100% of the unused balance of the Lease Negotiation Holdback.
Outlook, Risks, and Management Commentary
Operational Progress: As of November 30, 2023, Neurogene announced the dosing of its first two female pediatric patients with Rett syndrome in its Phase 1/2 trial of NGN-401. The drug has been well-tolerated with no treatment-emergent serious adverse events reported to date.
Research Collaboration: The Company amended its Master Research Collaboration Agreement with the University of Edinburgh on November 29, 2023, extending the term by three years to continue gene therapy development.
Risk Factors: The filing highlights significant risks typical of early-stage biopharmaceutical companies, including limited operating history, the need to raise additional capital, uncertainties in clinical trial outcomes, regulatory approval challenges, and reliance on third-party manufacturers. Forward-looking statements are subject to these uncertainties.
Investor Verification Checklist
- Capital Dilution: Verify the impact of the 16.8 million fully diluted share count (including pre-funded warrants) on existing shareholder ownership percentages.
- CVR Valuation: Assess the potential value of the Contingent Value Rights, specifically the likelihood of realizing savings from the Seattle lease sublease and the sales tax refund.
- Cash Runway: Review the unaudited pro forma financial statements (Exhibit 99.5) to determine the combined company's cash position and runway following the $95 million financing.
- Clinical Data: Monitor upcoming data readouts from the NGN-401 Phase 1/2 trial for Rett syndrome to validate the safety and efficacy profile.
- Lock-Up Periods: Note that certain stockholders and executives are subject to 180-day lock-up agreements, which may affect near-term share supply.